Related Experiment Video
Updated: Mar 22, 2026

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
MICA Mutant A5.1 Influences BK Polyomavirus Reactivation and Associated Nephropathy After Kidney Transplantation
Pierre Tonnerre1, Nathalie Gérard1, Pierre-Jean Gavlovsky1
1INSERM, UMR1064, LabEx Transplantex, LabEx IGO and IHU-CESTI CHU Nantes, Institut de Transplantation et de Recherche en Transplantation-Urologie-Néphrologie, ITUN LUNAM, Université de Nantes, Faculté de Médecine.
Background:
BK polyomavirus (BKPyV) frequently reactivates in kidney transplant recipients during immunosuppressive therapy and triggers BKPyV-associated nephropathy and graft rejection. Determining effective risk factors for BKPyV reactivation is required to achieve efficient prevention.
Methods:
This study investigated the role of major histocompatibility complex (MHC) class I-related chain A (MICA) in BKPyV reactivation in a cohort of 144 transplant donor/recipient pairs, including recipients with no reactivation (controllers) and those with mild (virurics) or severe (viremics) BKPyV reactivation after graft receipt.
Results:
We show that, in the kidney, MICA is predominantly expressed in tubule epithelial cells, the natural targets of BKPyV, questioning a role for MICA in the immune control of BKPyV infection. Focusing on MICA genotype, we found a lower incidence of BKPyV reactivation in recipients of a renal graft from a donor carrying the MICA A5.1 mutant, which encodes a truncated nonconventional MICA. We established that a mismatch for MICA A5.1 between transplant donor and recipient is critical for BKPyV reactivation and BKPyV-associated nephropathy. Functionally, we found that a low prevalence of BKPyV reactivation was associated with elevated anti-MICA sensitization and reduced plasma level of soluble MICA in recipients, 2 potential effector mechanisms.
Discussions:
These findings identify the MHC-related MICA as an immunogenetic factor that may functionally influence anti-BKPyV immune responses and infection outcomes.
Insights
Major histocompatibility complex (MHC) class I-related chain A (MICA) mismatch is critical for BK polyomavirus (BKPyV) reactivation after kidney transplants. This finding may improve prevention strategies for BKPyV-associated nephropathy.
Area of Science:
- Immunogenetics
- Transplantation immunology
- Virology
Background:
- BK polyomavirus (BKPyV) reactivation is common in kidney transplant recipients, leading to nephropathy and graft loss.
- Identifying risk factors for BKPyV reactivation is crucial for effective prevention strategies.
Purpose of the Study:
- To investigate the role of major histocompatibility complex (MHC) class I-related chain A (MICA) in BKPyV reactivation.
- To determine if MICA genotype and donor-recipient mismatch influence BKPyV reactivation and outcomes.
Main Methods:
- Analysis of 144 kidney transplant donor/recipient pairs.
- Assessment of BKPyV reactivation levels (controllers, virurics, viremic).
- Genotyping for MICA, including the A5.1 variant, and analysis of anti-MICA sensitization and soluble MICA levels.
Main Results:
- MICA is expressed in kidney tubule epithelial cells, the primary targets of BKPyV.
- Recipients with a donor carrying the MICA A5.1 mutant showed lower BKPyV reactivation rates.
- MICA A5.1 mismatch between donor and recipient was critical for BKPyV reactivation and nephropathy.
- Low BKPyV reactivation correlated with elevated anti-MICA sensitization and reduced soluble MICA.
Conclusions:
- MICA acts as an immunogenetic factor influencing anti-BKPyV immune responses.
- MICA A5.1 mismatch is a significant risk factor for BKPyV reactivation and associated nephropathy.
- These findings may inform strategies to prevent BKPyV reactivation in kidney transplant recipients.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013